Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034

February marks Precision Medicine Month, with advancements in genomics, data analytics, and targeted therapies continuing to shape the future of medicine. The precision medicine market is rapidly expanding, driven by ongoing advancements and increasing adoption across the healthcare sector. Recently, Precedence Research reported that the global precision medicine market was valued at USD$ 102.17 billion in 2024 and is projected to grow to USD$ 119.03 billion in 2025. Analysts expect the market to reach approximately USD$ 470.53 billion by 2034, growing at a compound annual growth rate (CAGR) of 16.5% from 2024 to 2034.

Precision medicine tailoring treatments using genetics, with NGS advancing genomics

Precision medicine takes an innovative approach to biomedical science, focusing on patient-specific genetic research to develop advanced diagnostics and treatments. This market centers on creating personalized medicines, therapies, and technologies tailored to an individual’s genetic, environmental, and behavioral profile. Next-generation sequencing (NGS) plays a key role in this advancement, using extensive databases, bioinformatics tools, and sequencing techniques to analyze large genomes and refine precision medicine strategies.

The therapeutics segment dominated the precision medicine market in 2023 and will grow at a compound annual growth rate (CAGR) of 15.9% during the forecast period. Hospitals held the largest market share, accounting for 61.0% of revenue in 2023, as they provide the ideal environment for personalized medicine with their advanced infrastructure and access to diverse patient populations. According to a 2022 report by the Personalized Medicine Coalition (PMC), personalized medicines have made up more than one in four FDA-approved drugs since 2014.

In the U.S., the National Institutes of Health (NIH) launched the All of Us Research Program, where approximately one million participants contribute genetic data, join clinical trials, and access their electronic health records. With these innovations, doctors, researchers, and clinicians are able to provide more accurate risk assessments, diagnoses, treatments, and preventive care. To ensure safety and effectiveness, the U.S. Food and Drug Administration (FDA) has set guidelines for the design, development, and validation of NGS technology and clinical tests.

The market is projected to reach USD$ 470.53 billion by 2034, growing at a CAGR of 16.5% from 2024.

2023 Showcased North America leading the market with 53.62%, followed by Europe at 23% and APAC at 17%

Analysts project that the U.S. precision medicine market will grow from USD 49.79 billion in 2024 to USD 232.49 billion by 2034, maintaining a CAGR of 16.7% over the decade. North America led the precision medicine market, representing 53.62% of the total share in 2023. As of now, the California Initiative to Advance Precision Medicine is strengthening patient-centered research by collaborating with healthcare stakeholders across the state. This initiative fosters innovation by bringing together scientists, entrepreneurs, and patient participants to transform large data sets into improved health outcomes.

Strategic collaborations and government initiatives are driving Asia Pacific to become the fastest-growing region in the precision medicine market. To do so, the Asia Pacific Medical Technology Association (APACMed) is promoting next-generation sequencing (NGS) in cancer care to enhance precision treatments. Additionally, APACMed is setting policy standards to integrate genomic and precision medicine into national healthcare strategies, improving clinical outcomes and optimizing healthcare spending. The region is also investing in national genomics infrastructure and NGS-based drug trials, expanding patient access to targeted therapies. Furthermore, regulatory, reimbursement, and clinical policies are ensuring timely access to NGS testing, while digital technologies are fostering multidisciplinary collaboration.

In 2023, North America led the precision medicine market with 53.62%, followed by Europe at 23% and APAC at 17%.

Related posts:

“Project Oxygen”of Precision Medicine Exclusive Interview of Dr. Chris Tsai, Founder of Bionet The Defining Role of Metabolism in Human Health and Disease ADC Market Set to Boom: $47 Billion Jump Ahead, but Side Effects Still Pose Key Challenge GSK Secures Approval From Chinese NMPA for Nucala, its Add-On-Therapy to Treat CRSwNP

Author

Denisse Sandoval